Is SCHD’s Recent Drawdown a Buying Opportunity Like PEP – Here’s What I Discovered
The recent correction in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has many passive income investors wondering if it’s time to load up or jump out. With the S&P 500 on its way to new highs, the dividend stock-heavy SCHD has been in a bit of a tough spot, still down 10% from its own […]
Studies Address Muscle Loss Caused By GLP-1 Drugs
By Dennis Thompson HealthDay ReporterTUESDAY, June 24, 2025 (HealthDay News) — GLP-1 drugs like Ozempic and Zepbound are great at promoting weight…
Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative
Post Content
Big Pharma Faceoff: Wegovy To Join Mounjaro In India’s Booming Weight Loss Drug Market
While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical trials suggest may provide superior weight loss outcomes
Amycretin delivers unprecedented weight loss in early trial for obesity treatment
Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.
STAT+: GLP-1 drug helped type 1 diabetes patients keep healthy glucose levels and lose weight
Obesity drugs were first approved to treat type 2 diabetes, but there’s a growing movement to test them in type 1 diabetes, too. Research presented Monday at a large diabetes meeting showed some promise for this approach. Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood […]
Significant Weight Loss With CagriSema, But Less Than Hoped
Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes improve their health. Medscape Medical News
Experimental drug helps patients lose nearly a quarter of body weight in early trials
An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that […]
Weekly semaglutide improves blood sugar and weight in adults with type 1 diabetes, clinical trial finds
A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with type 1 diabetes who use automated insulin delivery systems.
Ozempic Shows Benefit in Type 1 Diabetes Patients With Obesity
(MedPage Today) — CHICAGO — Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed.
In this 26-week, double-blind trial of 72 adults, 36% who received 1 mg of the…